Orphan drug development for targeting chronic myeloid leukemia stem cells. (2nd August 2016)

• Record Type: Journal Article
• Authors: Xie, Xueqin; Zhang, Haojian
• Is Part Of: Expert opinion on orphan drugs. Volume 4:Number 8(2016:Aug.)
• Page Start: 837
• Page End: 843
• Publication Date: 2016-08-02
• Subjects: Chronic myeloid leukemia -- BCR-ABL -- leukemia stem cell -- tyrosine kinase inhibitors -- PPARγ agonist; Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• DOI: 10.1080/21678707.2016.1202820
• Languages: English
• ISSNs: 2167-8707

Abstract

ABSTRACT: Introduction : Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease that derives from an abnormal hematopoietic stem cell (HSC) harboring the Philadelphia (Ph + ) chromosome. Tyrosine kinase inhibitors (TKIs) successfully target BCR-ABL oncoprotein, and block the cellular proliferation and survival, thereby dramatically increase the long-term survival rates of the majority of CML patients in chronic phase. However, TKIs are unable to deplete leukemia stem cells, which are responsible for the relapse of CML patients. Therefore, in CML biology, the limitations of TKIs require us to seek effective strategy to target leukemia stem cells (LSCs). Areas covered : This review first summarizes the characterization of CML and the features of several tyrosine kinase inhibitors, which are currently in use in clinics. We further discuss leukemia stem cells and focus on the new potential target-PPARγ and its function in eradicating LSCs of CML. Expert opinion : Because of the inability of TKIs to target CML LSCs, the current major goal in CML biology is to explore an effective strategy to target LSCs. Combining an agent targeting LSC with TKIs might be the right direction in the future. PPARγ is essential for regulating the survival of LSCs, and combination of PPARγ agonists with TKIs effectively depletes LSCs, providing a promising strategy for curing CML. However, the function of PPARγ agonists should be further assessed in clinical trials, and side effects should be carefully evaluated.